Stockreport

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Inc.  (NGNE) 
PDF Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndromeNeurogene to advance NGN-401 at 1E15 vg doseExpects to provide [Read more]